Google
EGRX 株価分析 — Eagle Pharmaceuticals Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
EGRX に関するよくある質問
EGRXのPER（株価収益率）は？
Eagle Pharmaceuticals Inc（EGRX）は現在PER 0.17倍で取引されています。
EGRXのROE（自己資本利益率）は？
Eagle Pharmaceuticals IncのROEは6.18%です。
EGRXの配当利回りは？
Eagle Pharmaceuticals Incの配当利回りは0.00%です。
EGRXの品質スコア（Quality Score）は？
当社のAIはEGRXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EGRXは今が買い時ですか？
当社AIのタイミングスコアは100点中4点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EGRXはどのセクターに属しますか？
Eagle Pharmaceuticals IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
EGRX AI Analysis Summary
Our AI summary for EGRX: Eagle Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.17, ROE of 6.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 4/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.37
Price
-0.01
(-1.64%)
Day Change
|
|
|---|
EGRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
131
|
| Magic Formula Rank by ROE |
131
|
| Magic Formula Rank by ROIC |
100
GOOD
|
| Price | 0.37 |
| PBV / Sector |
0.01 / 10.19
GREAT
|
| Earning Per Share | 1.75 |
| PE / Sector |
0.17 / 31.74
GREAT
|
| PEG or PE/Growth / Sector |
N/A / -0.02
|
| Average 1M Daily Value |
1050.243825000000
|
| Average 1W Daily Value |
3312.479000000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:55 |
| Symbol | EGRX |
| Name | EAGLE PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 13.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3.29 / 10,556.24 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
Phone: 201 326 5300
Website: https://www.eagleus.com
Employees: 134
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
